Tryptophan Steal and the De Novo Synthesis Paradox

The de novo synthesis of NAD+ begins with the essential amino acid L-Tryptophan. Under homeostatic conditions, a small fraction of tryptophan is converted into serotonin and melatonin. However, over 95 percent is processed via the Kynurenine pathway. In the presence of chronic stress or infection, the enzymes IDO1 and TDO are upregulated, initiating the 'Tryptophan Steal.' This biological prioritization shifts tryptophan away from the brain—leading to anxiety and depression—towards the production of Quinolinic Acid and eventually NAD+. The paradox lies in the efficiency of this pathway.

While it serves as a backup, the accumulation of Quinolinic Acid is neurotoxic. Furthermore, the final step in this pathway is governed by ACMSD (aminocarboxymuconate-semialdehyde decarboxylase). When ACMSD is overactive, it diverts intermediates away from NAD+ production, causing a 'leaky' synthesis route that fails to provide the cell with sufficient energy despite the depletion of tryptophan. Mainstream psychiatry treats the serotonin deficiency with SSRIs but ignores the underlying metabolic drive for NAD+ that caused the depletion. Evidence from the University of Lausanne suggests that inhibiting ACMSD can significantly boost NAD+ levels in the liver and kidneys, providing a therapeutic target that doesn't rely on external precursors.

For the health-educated individual, this means that 'brain fog' and mood shifts are often early indicators of a metabolic crisis. Supporting the de novo pathway requires more than just B3; it requires the management of cortisol and systemic inflammation to ensure that the Kynurenine pathway does not become a source of neurotoxicity. Utilizing cofactors like P5P (active Vitamin B6) is essential for the enzymes that navigate the Kynurenine branch points, ensuring that the 'steal' results in energy production rather than metabolic waste.